NON-MEDICAL SWITCH BETWEEN ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS - A MULTICENTRE STUDY ON EFFICACY AND DRUG SUSTAINABILITY

被引:0
|
作者
Lontai, Livia
Gonczi, Lorant
Balogh, Fruzsina
Komlodi, Nora
Resal, Tamas
Farkas, Klaudia
Molnar, Tamas
Miheller, Pal
Golovics, Petra A.
Schafer, Eszter
Szamosi, Tamas
Ilias, Akos
Lakatos, Peter L.
机构
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Su1507
引用
收藏
页码:S606 / S606
页数:1
相关论文
共 50 条
  • [1] Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients - a multicentre study on efficacy and drug sustainability
    Lontai, L.
    Gonczi, L.
    Balogh, F.
    Komlodi, N.
    Resal, T.
    Farkas, K.
    Molnar, T.
    Golovics, P.
    Schafer, E.
    Szamosi, T.
    Miheller, P.
    Ilias, A.
    Lakatos, P. L.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I518 - I519
  • [2] Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients - a multicentre study on efficacy and drug sustainability
    Lontai, L.
    Gonczi, L.
    Balogh, F.
    Komlodi, N.
    Resal, T.
    Farkas, K.
    Molnar, T.
    Golovics, P.
    Schafer, E.
    Szamosi, T.
    Miheller, P.
    Ilias, A.
    Lakatos, P. L.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I518 - I519
  • [3] Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study
    Lontai, Livia
    Gonczi, Lorant
    Balogh, Fruzsina
    Komlodi, Nora
    Resal, Tamas
    Farkas, Klaudia
    Molnar, Tamas
    Miheller, Pal
    Golovics, Petra A.
    Schafer, Eszter
    Szamosi, Tamas
    Ilias, Akos
    Lakatos, Peter L.
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (12) : 1639 - 1645
  • [4] Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia
    Anderson, Emilia
    Waller, Karen
    Tamilarasan, Aravind Gokul
    Lin, Huiyu
    Paramsothy, Sudarshan
    Leong, Rupert W.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (08) : 819 - 825
  • [5] Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy
    Tarsi, Antonio
    Mocci, Giammarco
    Cuomo, Antonio
    Ferronato, Antonio
    Elisei, Walter
    Picchio, Marcello
    Maconi, Giovanni
    Scaldaferri, Franco
    Papa, Alfredo
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2022, 31 (04) : 411 - 416
  • [6] DIFFERENT FAILURE RATES AFTER NON-MEDICAL SWITCHING 744 PATIENTS FROM ADALIMUMAB ORIGINATOR TO 2 ADALIMUMAB BIOSIMILARS
    Rosembert, Denise
    Malaviya, Anshuman
    How, Jane
    Toh, Fiona
    Tomlinson, Jacqueline
    Nightingale, Allison
    Garcia-Sueiro, Cristina
    Herbert, Pippa
    Magsino, Julien
    Roe, Maria
    Jadon, Deepak
    Norris, Paul
    Raine, Tim
    GUT, 2021, 70 : A115 - A115
  • [7] Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with Inflammatory Bowel Disease: Results of a multicenter survey
    Bikar, A.
    Farkas, N.
    Resal, T.
    Szepes, Z.
    Klaudia, F.
    Vincze, A.
    Miheller, P.
    Molnar, T.
    Sarlos, P.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 928 - 928
  • [8] Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey
    Sarlos, Patricia
    Bikar, Alexander
    Farkas, Nelli
    Resal, Tamas
    Szepes, Zoltan
    Farkas, Klaudia
    Nagy, Ferenc
    Vincze, Aron
    Miheller, Pal
    Molnar, Tamas
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (08) : 827 - 832
  • [9] Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis
    Loft, Nikolai
    Egeberg, Alexander
    Rasmussen, Mads Kirchheiner
    Bryld, Lars Erik
    Nissen, Christoffer Valdemar
    Dam, Tomas Norman
    Ajgeiy, Kawa Khaled
    Iversen, Lars
    Skov, Lone
    JAMA DERMATOLOGY, 2021, 157 (06) : 676 - 683
  • [10] Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study
    Jose Casanova, Maria
    Nantes, Oscar
    Varela, Pilar
    Vela-Gonzalez, Milagros
    Rivero, Montserrat
    Sierra-Gabarda, Olivia
    Riestra, Sabino
    Barreiro-de Acosta, Manuel
    del Mar Martin-Rodriguez, Maria
    Jerusalen Gargallo-Puyuelo, Carla
    Reygosa, Cristina
    Munoz, Roser
    Garcia de la Filia-Molina, Irene
    Nunez-Ortiz, Andrea
    Kolle, Lilyan
    Calafat, Margalida
    Maria Huguet, Jose
    Iglesias-Flores, Eva
    de Jesus Martinez-Perez, Teresa
    Bosch, Orencio
    Maria Duque-Alcorta, Jose
    Frago-Larramona, Santiago
    Van Domselaar, Manuel
    Manuel Gonzalez-Cosano, Victor
    Bujanda, Luis
    Rubio, Saioa
    Mancebo, Alejo
    Castro, Beatriz
    Garcia-Lopez, Santiago
    de Francisco, Ruth
    Nieto-Garcia, Laura
    Laredo, Viviana
    Gutierrez-Casbas, Ana
    Mesonero, Francisco
    Leo-Carnerero, Eduardo
    Canete, Fiorella
    Ruiz, Lucia
    Gros, Beatriz
    del Moral-Martinez, Maria
    Rodriguez, Cristina
    Chaparro, Maria
    Gisbert, Javier P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (01) : 60 - 70